Tasmar is a drug owned by Bausch Health Us Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 19, 2012. Details of Tasmar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5476875 | Catechol derivatives |
Dec, 2012
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Tasmar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tasmar's family patents as well as insights into ongoing legal events on those patents.
Tasmar's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tasmar's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 19, 2012 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tasmar Generic API suppliers:
Tolcapone is the generic name for the brand Tasmar. 4 different companies have already filed for the generic of Tasmar, with Alvogen having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tasmar's generic
Alternative Brands for Tasmar
Tasmar which is used for managing symptoms of Parkinson's disease., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim |
| |||||||||||||||
| Impax |
| |||||||||||||||
| Orion Pharma |
| |||||||||||||||
| Supernus Pharms |
| |||||||||||||||
| Teva |
| |||||||||||||||
About Tasmar
Tasmar is a drug owned by Bausch Health Us Llc. It is used for managing symptoms of Parkinson's disease. Tasmar uses Tolcapone as an active ingredient. Tasmar was launched by Bausch in 1998.
Approval Date:
Tasmar was approved by FDA for market use on 29 January, 1998.
Active Ingredient:
Tasmar uses Tolcapone as the active ingredient. Check out other Drugs and Companies using Tolcapone ingredient
Treatment:
Tasmar is used for managing symptoms of Parkinson's disease.
Dosage:
Tasmar is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | TABLET | Discontinued | ORAL |
| 100MG | TABLET | Prescription | ORAL |